Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Victoria Y. Strauss, Rachel Shaw, Pradeep S. Virdee, Christopher N. Hurt, Elizabeth Ward, Bethan Tranter, Neel Patel, John Bridgewater, Philip Parsons, Ganesh Radhakrishna, Eric O’Neill, David Sebag-Montefiore, Maria Hawkins, Pippa G. Corrie, Timothy Maughan, Somnath Mukherjee

ABSTRACT

BACKGROUND: Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2). METHODS: Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose (arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19-9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme. DISCUSSION: SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen. TRIAL REGISTRATION: Eudract No: 2013-004968-56; ClinicalTrials.gov : NCT02024009. More... »

PAGES

121

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z

DOI

http://dx.doi.org/10.1186/s12885-019-5307-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111916370

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30717707


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Centre for Statistics in Medicine, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Strauss", 
        "givenName": "Victoria Y.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Oncology Clinical Trials Office, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shaw", 
        "givenName": "Rachel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Centre for Statistics in Medicine, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Virdee", 
        "givenName": "Pradeep S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiff University", 
          "id": "https://www.grid.ac/institutes/grid.5600.3", 
          "name": [
            "Centre for Trials Research, Cardiff University, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hurt", 
        "givenName": "Christopher N.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol Royal Infirmary", 
          "id": "https://www.grid.ac/institutes/grid.418482.3", 
          "name": [
            "Clinical Trials and Evaluation Unit, Bristol Royal Infirmary, Bristol, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ward", 
        "givenName": "Elizabeth", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Velindre Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.470144.2", 
          "name": [
            "Pharmacy Department, Velindre Cancer Centre, Velindre NHS University Trust, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tranter", 
        "givenName": "Bethan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Churchill Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415719.f", 
          "name": [
            "Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "Neel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University College Hospital", 
          "id": "https://www.grid.ac/institutes/grid.439749.4", 
          "name": [
            "Department of Oncology, University College London Hospitals, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bridgewater", 
        "givenName": "John", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Velindre Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.470144.2", 
          "name": [
            "Cardiff NCRI RTTQA group, Department of Medical Physics, Velindre Cancer Centre, Cardiff, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parsons", 
        "givenName": "Philip", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Christie Hospital NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.412917.8", 
          "name": [
            "Oncology Department, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Radhakrishna", 
        "givenName": "Ganesh", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Neill", 
        "givenName": "Eric", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Leeds, Leeds Cancer Centre, St James\u2019s University Hospital, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sebag-Montefiore", 
        "givenName": "David", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hawkins", 
        "givenName": "Maria", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Addenbrooke's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.120073.7", 
          "name": [
            "Cambridge Cancer Centre, Addenbrooke\u2019s Hospital, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corrie", 
        "givenName": "Pippa G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maughan", 
        "givenName": "Timothy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Oxford", 
          "id": "https://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukherjee", 
        "givenName": "Somnath", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-1324", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000642406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-1239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000833623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.2355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008041290"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-09-0657", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011022022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2004.04.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012646128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1748-717x-7-156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013784022", 
          "https://doi.org/10.1186/1748-717x-7-156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2009.04.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014271047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.17.7188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017430935"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.radonc.2016.03.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017501197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn281", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019387985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-1220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022622708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-0757", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026599802"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2012.02.051", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033040622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.8038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034167619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70021-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041381779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pmed.1000267", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045271156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2007.01.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046097055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.7712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046116901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2003.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048100421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2003.11.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051174392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2006.12.053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052268854"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.7.5.5728", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072294963"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075125171", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.31.18_suppl.lba4003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083394061"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2).\nMETHODS: Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C\u2009+\u2009D) or standard-dose (arms A\u2009+\u2009B) radiotherapy with (arms A\u2009+\u2009C) or without (arms B\u2009+\u2009D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19-9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme.\nDISCUSSION: SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen.\nTRIAL REGISTRATION: Eudract No: 2013-004968-56; ClinicalTrials.gov : NCT02024009.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-019-5307-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine \u00b1 nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)", 
    "pagination": "121", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c54dadc216101b4b8d376c582dc8a1994bc1d0239c3cccc5ccb65077ebf747ff"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30717707"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-019-5307-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111916370"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-019-5307-z", 
      "https://app.dimensions.ai/details/publication/pub.1111916370"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000329_0000000329/records_74704_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-019-5307-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5307-z'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      53 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-019-5307-z schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N706a2d0740e549cbad0b6276cbe11eca
4 schema:citation sg:pub.10.1186/1748-717x-7-156
5 https://app.dimensions.ai/details/publication/pub.1075125171
6 https://doi.org/10.1016/j.ijrobp.2003.11.003
7 https://doi.org/10.1016/j.ijrobp.2003.11.019
8 https://doi.org/10.1016/j.ijrobp.2004.04.004
9 https://doi.org/10.1016/j.ijrobp.2006.12.053
10 https://doi.org/10.1016/j.ijrobp.2007.01.005
11 https://doi.org/10.1016/j.ijrobp.2012.02.051
12 https://doi.org/10.1016/j.radonc.2009.04.015
13 https://doi.org/10.1016/j.radonc.2016.03.021
14 https://doi.org/10.1016/s1470-2045(13)70021-4
15 https://doi.org/10.1093/annonc/mdn281
16 https://doi.org/10.1158/0008-5472.can-05-1220
17 https://doi.org/10.1158/0008-5472.can-06-1239
18 https://doi.org/10.1158/0008-5472.can-08-0757
19 https://doi.org/10.1158/0008-5472.can-09-0657
20 https://doi.org/10.1158/1078-0432.ccr-09-1324
21 https://doi.org/10.1200/jco.2007.12.7712
22 https://doi.org/10.1200/jco.2007.15.2355
23 https://doi.org/10.1200/jco.2008.17.7188
24 https://doi.org/10.1200/jco.2010.33.8038
25 https://doi.org/10.1200/jco.2013.31.18_suppl.lba4003
26 https://doi.org/10.1371/journal.pmed.1000267
27 https://doi.org/10.4161/cbt.7.5.5728
28 schema:datePublished 2019-12
29 schema:datePublishedReg 2019-12-01
30 schema:description BACKGROUND: Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2). METHODS: Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose (arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19-9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme. DISCUSSION: SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen. TRIAL REGISTRATION: Eudract No: 2013-004968-56; ClinicalTrials.gov : NCT02024009.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N1bf80a7e42b141e3b00353a287623e26
35 N57b7006033c64be9909e97642eb9e0e1
36 sg:journal.1024632
37 schema:name Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
38 schema:pagination 121
39 schema:productId N732ff048064f4b7f981c720abb897545
40 N79cd54ec5a2f4fcf904b1f4ebd30745a
41 Nafe7007a222c472488c62e502955b069
42 Nb352552bdde042bdbc324d1872df4daf
43 Nfe680fc2acef416199bca1a9025d04d8
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111916370
45 https://doi.org/10.1186/s12885-019-5307-z
46 schema:sdDatePublished 2019-04-11T09:01
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N17655ea4443e4088a206e0f982fb4a47
49 schema:url https://link.springer.com/10.1186%2Fs12885-019-5307-z
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N09fec512eb274104b6f32ec44990d61d rdf:first N49485e5db98d4d37ba0e72694dd0ddff
54 rdf:rest Nb000363062214799a997cfecd7073054
55 N0f9436027f4a4217b8977087e2f5724d schema:affiliation https://www.grid.ac/institutes/grid.4991.5
56 schema:familyName Shaw
57 schema:givenName Rachel
58 rdf:type schema:Person
59 N17655ea4443e4088a206e0f982fb4a47 schema:name Springer Nature - SN SciGraph project
60 rdf:type schema:Organization
61 N182ed32a45974e6196445ae5fac41414 schema:affiliation https://www.grid.ac/institutes/grid.470144.2
62 schema:familyName Tranter
63 schema:givenName Bethan
64 rdf:type schema:Person
65 N1bf80a7e42b141e3b00353a287623e26 schema:issueNumber 1
66 rdf:type schema:PublicationIssue
67 N216285f43f784dcd850b2309937bb09a rdf:first Nfc8f409b7e1f4571ae53e04c972bc77c
68 rdf:rest Na7583fe6dc034fa98a383927c98ef059
69 N2354074ce9a14e0299d69f4026885272 rdf:first N4fd69b5804174c58aa30fcfea7cd7693
70 rdf:rest N31f8582af9424ecba2127470e4eb14a3
71 N2e8b8299e75d4d08bc5596606052193d rdf:first N362aaf63308349218be59de9c14bca1c
72 rdf:rest rdf:nil
73 N31f8582af9424ecba2127470e4eb14a3 rdf:first Nfeae137d55a04150994c81499ca71cb5
74 rdf:rest N2e8b8299e75d4d08bc5596606052193d
75 N34351ae6f0be42a0942504b2f6238982 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
76 schema:familyName Strauss
77 schema:givenName Victoria Y.
78 rdf:type schema:Person
79 N362aaf63308349218be59de9c14bca1c schema:affiliation https://www.grid.ac/institutes/grid.4991.5
80 schema:familyName Mukherjee
81 schema:givenName Somnath
82 rdf:type schema:Person
83 N3682bd1d75f34d628be023b9742fe3d1 schema:affiliation https://www.grid.ac/institutes/grid.415719.f
84 schema:familyName Patel
85 schema:givenName Neel
86 rdf:type schema:Person
87 N402684ef25f54d2c8153907bbb34f1ab schema:affiliation https://www.grid.ac/institutes/grid.4991.5
88 schema:familyName Virdee
89 schema:givenName Pradeep S.
90 rdf:type schema:Person
91 N48a44326281f486fb5f0928429e60c0e schema:affiliation https://www.grid.ac/institutes/grid.4991.5
92 schema:familyName O’Neill
93 schema:givenName Eric
94 rdf:type schema:Person
95 N49485e5db98d4d37ba0e72694dd0ddff schema:affiliation https://www.grid.ac/institutes/grid.470144.2
96 schema:familyName Parsons
97 schema:givenName Philip
98 rdf:type schema:Person
99 N4fd69b5804174c58aa30fcfea7cd7693 schema:affiliation https://www.grid.ac/institutes/grid.120073.7
100 schema:familyName Corrie
101 schema:givenName Pippa G.
102 rdf:type schema:Person
103 N50c25cf9dda542b082035ab027dbdc7f rdf:first Naba6a2e9b3194585bbc4247147447a34
104 rdf:rest N7439121cf1ad42b3aacd649a2d23810c
105 N52414cb6f2474c21bcc9f76eb3e80caa rdf:first N3682bd1d75f34d628be023b9742fe3d1
106 rdf:rest Nbebe179689eb4cd1ba0d5d5c4b819e17
107 N56702db3726f4628b269049c2ddffe0f rdf:first N0f9436027f4a4217b8977087e2f5724d
108 rdf:rest N7351c5212a554958bac6691bb9460481
109 N57b7006033c64be9909e97642eb9e0e1 schema:volumeNumber 19
110 rdf:type schema:PublicationVolume
111 N6b2f01b3016640c79093e8bccc51b97e schema:name University of Leeds, Leeds Cancer Centre, St James’s University Hospital, Leeds, UK
112 rdf:type schema:Organization
113 N706a2d0740e549cbad0b6276cbe11eca rdf:first N34351ae6f0be42a0942504b2f6238982
114 rdf:rest N56702db3726f4628b269049c2ddffe0f
115 N732ff048064f4b7f981c720abb897545 schema:name readcube_id
116 schema:value c54dadc216101b4b8d376c582dc8a1994bc1d0239c3cccc5ccb65077ebf747ff
117 rdf:type schema:PropertyValue
118 N7351c5212a554958bac6691bb9460481 rdf:first N402684ef25f54d2c8153907bbb34f1ab
119 rdf:rest N216285f43f784dcd850b2309937bb09a
120 N7439121cf1ad42b3aacd649a2d23810c rdf:first Ndbaf5e370e2c4b04ad5acb5334842b9d
121 rdf:rest N2354074ce9a14e0299d69f4026885272
122 N79cd54ec5a2f4fcf904b1f4ebd30745a schema:name pubmed_id
123 schema:value 30717707
124 rdf:type schema:PropertyValue
125 N7bd13168a1fc46ff9e7bf0afef9f54fd schema:affiliation https://www.grid.ac/institutes/grid.439749.4
126 schema:familyName Bridgewater
127 schema:givenName John
128 rdf:type schema:Person
129 N9253debd5a54429aaae22a85d05938a5 schema:affiliation https://www.grid.ac/institutes/grid.412917.8
130 schema:familyName Radhakrishna
131 schema:givenName Ganesh
132 rdf:type schema:Person
133 Na7583fe6dc034fa98a383927c98ef059 rdf:first Nae12be4b0b554593bf239fa801b8cead
134 rdf:rest Nc86f0fa04ca04d6ba61a808c4e1bdf06
135 Naba6a2e9b3194585bbc4247147447a34 schema:affiliation N6b2f01b3016640c79093e8bccc51b97e
136 schema:familyName Sebag-Montefiore
137 schema:givenName David
138 rdf:type schema:Person
139 Nae12be4b0b554593bf239fa801b8cead schema:affiliation https://www.grid.ac/institutes/grid.418482.3
140 schema:familyName Ward
141 schema:givenName Elizabeth
142 rdf:type schema:Person
143 Nafe7007a222c472488c62e502955b069 schema:name nlm_unique_id
144 schema:value 100967800
145 rdf:type schema:PropertyValue
146 Nb000363062214799a997cfecd7073054 rdf:first N9253debd5a54429aaae22a85d05938a5
147 rdf:rest Nb08e0b9d81234d5ea23b796ed78813a5
148 Nb08e0b9d81234d5ea23b796ed78813a5 rdf:first N48a44326281f486fb5f0928429e60c0e
149 rdf:rest N50c25cf9dda542b082035ab027dbdc7f
150 Nb352552bdde042bdbc324d1872df4daf schema:name dimensions_id
151 schema:value pub.1111916370
152 rdf:type schema:PropertyValue
153 Nbebe179689eb4cd1ba0d5d5c4b819e17 rdf:first N7bd13168a1fc46ff9e7bf0afef9f54fd
154 rdf:rest N09fec512eb274104b6f32ec44990d61d
155 Nc86f0fa04ca04d6ba61a808c4e1bdf06 rdf:first N182ed32a45974e6196445ae5fac41414
156 rdf:rest N52414cb6f2474c21bcc9f76eb3e80caa
157 Ndbaf5e370e2c4b04ad5acb5334842b9d schema:affiliation https://www.grid.ac/institutes/grid.4991.5
158 schema:familyName Hawkins
159 schema:givenName Maria
160 rdf:type schema:Person
161 Nfc8f409b7e1f4571ae53e04c972bc77c schema:affiliation https://www.grid.ac/institutes/grid.5600.3
162 schema:familyName Hurt
163 schema:givenName Christopher N.
164 rdf:type schema:Person
165 Nfe680fc2acef416199bca1a9025d04d8 schema:name doi
166 schema:value 10.1186/s12885-019-5307-z
167 rdf:type schema:PropertyValue
168 Nfeae137d55a04150994c81499ca71cb5 schema:affiliation https://www.grid.ac/institutes/grid.4991.5
169 schema:familyName Maughan
170 schema:givenName Timothy
171 rdf:type schema:Person
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
176 schema:name Oncology and Carcinogenesis
177 rdf:type schema:DefinedTerm
178 sg:journal.1024632 schema:issn 1471-2407
179 schema:name BMC Cancer
180 rdf:type schema:Periodical
181 sg:pub.10.1186/1748-717x-7-156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013784022
182 https://doi.org/10.1186/1748-717x-7-156
183 rdf:type schema:CreativeWork
184 https://app.dimensions.ai/details/publication/pub.1075125171 schema:CreativeWork
185 https://doi.org/10.1016/j.ijrobp.2003.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048100421
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/j.ijrobp.2003.11.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051174392
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/j.ijrobp.2004.04.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012646128
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.ijrobp.2006.12.053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052268854
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/j.ijrobp.2007.01.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046097055
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/j.ijrobp.2012.02.051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033040622
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/j.radonc.2009.04.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014271047
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/j.radonc.2016.03.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017501197
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/s1470-2045(13)70021-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041381779
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1093/annonc/mdn281 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019387985
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1158/0008-5472.can-05-1220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022622708
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1158/0008-5472.can-06-1239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000833623
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1158/0008-5472.can-08-0757 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026599802
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1158/0008-5472.can-09-0657 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011022022
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1158/1078-0432.ccr-09-1324 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000642406
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1200/jco.2007.12.7712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046116901
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1200/jco.2007.15.2355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008041290
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1200/jco.2008.17.7188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017430935
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1200/jco.2010.33.8038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034167619
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1200/jco.2013.31.18_suppl.lba4003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083394061
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1371/journal.pmed.1000267 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045271156
226 rdf:type schema:CreativeWork
227 https://doi.org/10.4161/cbt.7.5.5728 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072294963
228 rdf:type schema:CreativeWork
229 https://www.grid.ac/institutes/grid.120073.7 schema:alternateName Addenbrooke's Hospital
230 schema:name Cambridge Cancer Centre, Addenbrooke’s Hospital, Cambridge, UK
231 rdf:type schema:Organization
232 https://www.grid.ac/institutes/grid.412917.8 schema:alternateName Christie Hospital NHS Foundation Trust
233 schema:name Oncology Department, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK
234 rdf:type schema:Organization
235 https://www.grid.ac/institutes/grid.415719.f schema:alternateName Churchill Hospital
236 schema:name Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK
237 rdf:type schema:Organization
238 https://www.grid.ac/institutes/grid.418482.3 schema:alternateName Bristol Royal Infirmary
239 schema:name Clinical Trials and Evaluation Unit, Bristol Royal Infirmary, Bristol, UK
240 rdf:type schema:Organization
241 https://www.grid.ac/institutes/grid.439749.4 schema:alternateName University College Hospital
242 schema:name Department of Oncology, University College London Hospitals, London, UK
243 rdf:type schema:Organization
244 https://www.grid.ac/institutes/grid.470144.2 schema:alternateName Velindre Cancer Centre
245 schema:name Cardiff NCRI RTTQA group, Department of Medical Physics, Velindre Cancer Centre, Cardiff, UK
246 Pharmacy Department, Velindre Cancer Centre, Velindre NHS University Trust, Cardiff, UK
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.4991.5 schema:alternateName University of Oxford
249 schema:name Centre for Statistics in Medicine, University of Oxford, Oxford, UK
250 Department of Oncology, University of Oxford, CRUK MRC Oxford Institute for Radiation Oncology, Oxford, UK
251 Oncology Clinical Trials Office, University of Oxford, Oxford, UK
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.5600.3 schema:alternateName Cardiff University
254 schema:name Centre for Trials Research, Cardiff University, Cardiff, UK
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...